UrunYYasarHATurnaH, et al.Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. J Oncol Pharm Pract. Epub ahead of print 6 November 2018. DOI: 10.1177/1078155218805539.
2.
ShaverdianNLisbergAEBornazyanK, et al.Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol2017; 18: 895–903.
3.
HwangWLNiemierkoAHwangKL, et al.Clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy. JAMA Oncol2018; 4: 253–255.
4.
Twyman-Saint VictorCRechAJMaityA, et al.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature2015; 520: 373–377.
5.
EscorciaFEPostowMABarkerCA. Radiotherapy and immune checkpoint blockade for melanoma: a promising combinatorial strategy in need of further investigation. Cancer J2017; 23: 32–39.
6.
QinROlsonASinghB, et al.Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab. Int J Radiat Oncol Biol Phys2016; 96: 72–77.
7.
KollerKMMackleyHBLiuJ, et al.Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther2017; 18: 36–42.
8.
Chicas-SettRMorales-OrueIRodriguez-AbreuD, et al.Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: a systematic review. Clin Transl Radiat Oncol2018; 9: 5–11.
